Primary Progressive Multiple Sclerosis (PPMS) Treatment Global Market Report 2026
상품코드:1957696
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
원발성 진행형 다발성 경화증(PPMS) 치료 시장 규모는 최근 급성장하고 있습니다. 2025년 11억 6,000만 달러에서 2026년에는 13억 1,000만 달러에 이르고, CAGR 13.7%의 성장이 전망되고 있습니다. 지난 몇 년간 성장 요인으로는 PPMS의 치료 옵션이 제한적이라는 점, 증상 관리에 있어 코르티코스테로이드에 대한 의존도, 환자들의 PPMS에 대한 낮은 인식, 병원 약국 인프라 미비, 면역억제제 도입 지연 등을 꼽을 수 있습니다.
원발성 진행형 다발성 경화증(PPMS) 치료 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 21억 8,000만 달러에 이르고, CAGR은 13.5%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 표적형 단일클론항체 도입, 신경퇴행성 질환에 대한 연구 개발 증가, 병원 및 온라인 약국 네트워크 확대, 새로운 치료제의 규제 승인 증가, 환자 인식 개선 및 조기 진단 프로그램의 발전 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 PPMS(원발성 진행성 다발성 경화증)에 대한 단일클론항체 도입 증가, 증상 관리 및 삶의 질(QOL)에 대한 관심 증가, 정맥 투여 선호도 확대, 병원 및 전문 약국 채널 확대, 신규 치료제 및 병용요법 개발 등이 있습니다.
효과적인 치료법에 대한 수요 증가는 향후 몇 년 동안 원발성 진행성 다발성 경화증(PPMS) 치료제 시장의 성장을 견인할 것으로 예측됩니다. 효과적인 치료는 증상을 완화하고, 환자의 예후를 개선하거나 질병의 진행을 관리하는 의료적 개입을 의미합니다. 효과적인 치료에 대한 수요 증가는 주로 삶의 질을 향상시키기 위해 장기적인 치료와 고급 치료 솔루션을 필요로 하는 만성 및 복합 질환의 유병률 증가에 의해 주도되고 있습니다. PPMS에서 효과적인 치료는 염증을 줄이고 신경 기능을 유지함으로써 질환의 진행을 지연시켜 장애의 축적을 억제하고 장기적인 결과를 개선하여 환자가 일상 생활에서 더 큰 독립성을 유지할 수 있도록 돕습니다. 예를 들어, 미국 유전자 및 세포치료 전문기관인 미국 유전자 및 세포치료학회(ASGCT)에 따르면, 2024년 1월 기준 임상 3상 단계에 있는 유전자 치료제의 수는 2023년 33건으로 2022년 대비 10% 증가했으며, 2022년 3분기 이후 처음으로 분기 기준 증가세를 기록했습니다. 분기 기준 증가를 기록하였습니다. 따라서 효과적인 치료법에 대한 수요 증가가 원발성 진행성 다발성 경화증(PPMS) 치료제 시장의 성장을 견인하고 있습니다.
원발성 진행성 다발성 경화증(PPMS) 치료제 시장에서 사업을 전개하고 있는 주요 기업들은 다발성 경화증 관리 개선을 위해 단일클론항체 의약품 등 혁신적인 치료법 개발에 주력하고 있습니다. 단일클론항체 의약품은 염증과 신경 손상의 원인이 되는 면역세포와 단백질을 선택적으로 표적화하여 질병 활동을 억제하고 증상 진행을 지연시켜 다발성 경화증 치료에 도움을 줍니다. 예를 들어, 2024년 2월 인도에 본사를 둔 제약회사 로슈파마 인디아는 다발성 경화증 치료제로서 단일클론항체 치료제 '오클레바스(오크레리주맙)를 인도에 도입했습니다. 오크레바스는 국내 최초로 재발완화형 다발성경화증(RRMS)과 원발성 진행성 다발성경화증(PPMS) 모두에 대해 승인된 질환 조절 치료제로 인정받고 있습니다. 이 약은 다발성경화증과 관련된 비정상적인 면역반응에 관여하는 CD20 양성 B세포를 표적으로 하며, 1년에 2회 정맥주사(약 2시간)로 투여합니다. 이를 통해 환자에게 편리하고 효과적인 치료 옵션을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Primary progressive multiple sclerosis (PPMS) treatment involves medical and therapeutic strategies designed to manage and slow the progression of PPMS, a form of multiple sclerosis marked by a steady decline in neurological function from symptom onset without clear relapses or periods of remission. These treatments aim to modify disease activity, relieve symptoms, preserve mobility, and enhance overall quality of life.
The main drug types used in treating primary progressive multiple sclerosis (PPMS) include monoclonal antibodies, immunosuppressants, corticosteroids, and other drug categories. Monoclonal antibodies (mAbs) are laboratory-developed proteins engineered to selectively bind to specific antigens on diseased cells for therapeutic or diagnostic use. These medications are administered through various routes, including oral, intravenous, and other methods, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and additional distribution channels.
Tariffs have affected the ppms treatment market by increasing the cost of imported active pharmaceutical ingredients (apis) and biologics used in monoclonal antibodies and immunosuppressants. Segments such as intravenous therapies and specialty drugs are particularly impacted, with regions like Europe and Asia-Pacific experiencing higher import duties. This has led to increased treatment costs and supply chain realignments. Positively, tariffs have encouraged local manufacturing, regional production investments, and the development of cost-efficient biosimilars.
The primary progressive multiple sclerosis (ppms) treatment market research report is one of a series of new reports from The Business Research Company that provides primary progressive multiple sclerosis (ppms) treatment market statistics, including primary progressive multiple sclerosis (ppms) treatment industry global market size, regional shares, competitors with a primary progressive multiple sclerosis (ppms) treatment market share, detailed primary progressive multiple sclerosis (ppms) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the primary progressive multiple sclerosis (ppms) treatment industry. This primary progressive multiple sclerosis (ppms) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The primary progressive multiple sclerosis (ppms) treatment market size has grown rapidly in recent years. It will grow from $1.16 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to limited treatment options for ppms, reliance on corticosteroids for symptom management, low awareness of ppms among patients, underdeveloped hospital pharmacy infrastructure, slow adoption of immunosuppressants.
The primary progressive multiple sclerosis (ppms) treatment market size is expected to see rapid growth in the next few years. It will grow to $2.18 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to introduction of targeted monoclonal antibodies, increasing r&d in neurodegenerative disorders, expansion of hospital and online pharmacy networks, rising regulatory approvals for novel therapeutics, growth in patient awareness and early diagnosis programs. Major trends in the forecast period include rising adoption of monoclonal antibodies for ppms, increased focus on symptom management and quality of life, growth in intravenous drug administration preference, expansion of hospital and specialty pharmacy channels, development of novel therapeutics and combination therapies.
The increasing demand for effective treatments is anticipated to drive the growth of the primary progressive multiple sclerosis (PPMS) treatment market in the coming years. Effective treatments are medical interventions that alleviate symptoms, improve patient outcomes, or manage disease progression. The rising demand for effective treatments is mainly driven by the growing prevalence of chronic and complex conditions that require long-term care and advanced therapeutic solutions to enhance quality of life. In PPMS, effective treatments help slow disease progression by reducing inflammation and preserving neurological function, thereby limiting disability accumulation, improving long-term outcomes, and enabling patients to maintain greater independence in daily activities. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 in 2023, reflecting a 10% increase compared to 2022 and marking the first quarterly rise since the third quarter of 2022. Therefore, the growing demand for effective treatments is driving the growth of the primary progressive multiple sclerosis (PPMS) treatment market.
Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are emphasizing the development of innovative therapies, such as monoclonal antibody drugs, to improve multiple sclerosis management. Monoclonal antibody drugs help treat multiple sclerosis by selectively targeting immune cells or proteins responsible for inflammation and nerve damage, thereby reducing disease activity and slowing symptom progression. For example, in February 2024, Roche Pharma India, an India-based pharmaceutical company, introduced Ocrevus (ocrelizumab), a monoclonal antibody therapy, for the treatment of multiple sclerosis in India. Ocrevus is recognized as the first and only approved disease-modifying therapy for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug targets CD20-positive B cells involved in the abnormal immune response associated with MS and is administered as a twice-yearly intravenous infusion lasting approximately two hours, offering patients a convenient and effective treatment option.
In March 2024, Viatris Inc., a US-based healthcare company focused on expanding access to medicines, partnered with Mapi Pharma Ltd. to support the development and commercialization of GA Depot 40 mg for the treatment of multiple sclerosis. Through this collaboration, Viatris assists in advancing the regulatory and commercial pathway for GA Depot, a long-acting injectable formulation designed to improve treatment adherence and address unmet needs in multiple sclerosis care. Mapi Pharma Ltd. is an Israel-based pharmaceutical company specializing in depot and sustained-release drug delivery technologies for central nervous system disorders, including multiple sclerosis.
Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA
North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the primary progressive multiple sclerosis (ppms) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary progressive multiple sclerosis (PPMS) treatment market consists of sales of ocrelizumab (ocrevus), mitoxantrone, baclofen, modafinil and oxybutynin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses primary progressive multiple sclerosis (ppms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for primary progressive multiple sclerosis (ppms) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary progressive multiple sclerosis (ppms) treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Type: Monoclonal Antibodies; Immunosuppressants; Corticosteroids; Other Drug Types
2) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Ocrelizumab; Rituximab; Ofatumumab; Ublituximab
2) By Immunosuppressants: Methotrexate; Azathioprine; Mycophenolate Mofetil; Cyclophosphamide
3) By Corticosteroids: Methylprednisolone; Prednisone; Dexamethasone; Hydrocortisone
4) By Other Drug Types: Biotin; Ibudilast; Laquinimod; Idebenone
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Adoption Of Monoclonal Antibodies For Ppms
4.2.2 Increased Focus On Symptom Management And Quality Of Life
4.2.3 Growth In Intravenous Drug Administration Preference
4.2.4 Expansion Of Hospital And Specialty Pharmacy Channels
4.2.5 Development Of Novel Therapeutics And Combination Therapies
5. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Analysis Of End Use Industries
5.1 Neurologists And Healthcare Providers
5.2 Hospitals And Clinics
5.3 Specialty Pharmacies
5.4 Patients With Ppms
5.5 Research Institutions And Clinical Trial Centers
6. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size, Comparisons And Growth Rate Analysis
7.3. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.7. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Biotin, Ibudilast, Laquinimod, Idebenone
10. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regional And Country Analysis
10.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
12.1. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
13.1. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
14.1. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
15.1. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
16.1. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
17.1. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
19.1. South East Asia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
20.1. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
21.1. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22.1. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
23.1. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24.1. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25.1. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
27.1. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
28.1. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
29.1. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
31.1. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
32.1. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market
34.1. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
